Wellstar Through Its Wholly Owned Subsidiary Trillennium Medical Imaging (TMI) Announces the Development of the TMI Clinic

HOLLAND, Ohio--(BUSINESS WIRE)-- (OTCBB:WLSI) -- With the results of the clinical trial at Duke University Medical Center completed, and the pending publication of the results, TMI is pleased to announce the development of their new clinical imaging system. The technology that was used in the clinical trial to detect patterns of injury associated with the development of pressure ulcers before being clinically visible remains the same, but the addition of certain features and benefits will allow the imaging system to be a viable solution for any healthcare facility concerned with patient safety and decreasing pressure ulcer occurrence.

John Antonio, President and CEO of TMI stated: “By designing our own clinical version of the camera, we will control all aspects of our Imaging System and have the flexibility to incorporate all of the necessary functions to provide an innovative, bedside solution for the early detection of pressure ulcers. We will be able to seamlessly integrate into any Health Information System (HIS) that uses a barcode for patient identification, get immediate, real time analysis of the images at the bedside, and provide a means of documentation and data storage for the facility. This will provide health care officials with a multi-faceted tool that does the following:

  • Determines if a specific anatomic location has patterns of injury associated with the development of a pressure ulcer.
  • Provides the nursing staff and physicians with an immediate bedside analysis so that best practices can be implemented to prevent further skin damage and pressure ulcers.
  • Provides documentation to the administration that includes data interpretation of the image, time the image was acquired, and a full report analysis that can be attached to the patients’ permanent record.
  • Lowers the cost per unit by more than 40% to the company, thus giving the company a quicker path to profitability.
  • Make the system affordable to most all users.

“This will be a valuable tool in assessing patients that are admitted to a facility, daily skin assessments, and documenting patient condition upon discharge. This will provide patients with the highest level of care, while documenting every aspect of the process for the facility.”

Engineers have begun the development process complete with mechanical design and have identified all of the components. Four prototypes are scheduled to be delivered in June, with the final clinical version in October.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.


Investor Contact:
Falcon Financial Partners, LLC, 1-866-500-8985
Website is www.wellstar.us

KEYWORDS:   United States  North America  Ohio

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Medical Devices  Radiology